NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
Dana-Farber Cancer Institute
University Hospital Southampton NHS Foundation Trust
University of Birmingham
Innovent Biologics (Suzhou) Co. Ltd.
Kosin University Gospel Hospital
University College, London
Arbeitsgemeinschaft medikamentoese Tumortherapie